SHR-1802

SHR-1802 is a novel humanized monoclonal antibody that targets lymphocyte activation gene 3 (LAG-3), an immune checkpoint receptor. It specifically binds to LAG-3 and inhibits its interaction with ligands such as major histocompatibility complex class II (MHC-II), fibrinogen-like protein 1 (FGL1), galectin-3, and liver sinusoidal endothelial cell lectin. By blocking these interactions, SHR-1802 is designed to enhance anti-tumor immune responses. The drug has demonstrated a tolerable safety profile and preliminary antitumor activity in patients with advanced solid tumors in early-phase clinical trials[1][2][4]. Preclinical studies showed acceptable safety profiles and suggested enhanced tumor suppression when combined with the anti-PD-1 antibody camrelizumab[1].